<SEC-DOCUMENT>0001193125-24-076583.txt : 20240325
<SEC-HEADER>0001193125-24-076583.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325165618
ACCESSION NUMBER:		0001193125-24-076583
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INNOVATE Corp.
		CENTRAL INDEX KEY:			0001006837
		STANDARD INDUSTRIAL CLASSIFICATION:	FABRICATED STRUCTURAL METAL PRODUCTS [3440]
		ORGANIZATION NAME:           	04 Manufacturing
		IRS NUMBER:				541708481
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-274760
		FILM NUMBER:		24779964

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE
		STREET 2:		12TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		19546631147

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE
		STREET 2:		12TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HC2 HOLDINGS, INC.
		DATE OF NAME CHANGE:	20160809

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HC2 Holdings, Inc.
		DATE OF NAME CHANGE:	20140415

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTGi HOLDING, INC.
		DATE OF NAME CHANGE:	20131108
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d800312d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment No.&nbsp;1 to Prospectus Supplement Dated March&nbsp;8, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(To the Prospectus dated October&nbsp;6, 2023)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-274760</FONT></B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INNOVATE Corp. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Rights to Purchase up to $19.0 Million of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;1 to prospectus supplement amends the prospectus supplement dated March&nbsp;8, 2024 (the &#147;original prospectus
supplement&#148;).&nbsp;This Amendment No.&nbsp;1 to prospectus supplement is incorporated by reference into the original prospectus supplement and should be read in conjunction with the original prospectus supplement and the base prospectus dated
October&nbsp;6, 2023 (the &#147;base prospectus&#148;).&nbsp;This Amendment No.&nbsp;1 to prospectus supplement is not complete without, and may not be delivered or utilized, except in conjunction with the original prospectus supplement and the base
prospectus, including any amendments or supplements thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Extension of Subscription Period </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have distributed to the holders of record as of 5:00 p.m., New York City time, on March&nbsp;6, 2024 of our common stock, par value $0.001
per share (the &#147;common stock&#148;), our Series <FONT STYLE="white-space:nowrap">A-3</FONT> Convertible Participating Preferred Stock, par value $0.001 per share (the &#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred
Stock&#148;), our Series <FONT STYLE="white-space:nowrap">A-4</FONT> Convertible Participating Preferred Stock, par value $0.001 per share (the &#147;Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock&#148; and, together with the
Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, the &#147;preferred stock&#148;), those certain 2026 Convertible Notes (the &#147;convertible notes&#148;) transferable rights (the &#147;rights&#148;) to purchase up to an
aggregate of $19.0&nbsp;million of our common stock at a cash subscription price of $0.70 per share. Each rights allows you to purchase 0.2858 shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights are currently exercisable and, under the original prospectus supplement, were scheduled to expire if not exercised by 5:00 p.m.,
Eastern Time, on March&nbsp;25, 2024.&nbsp;As provided for in the original prospectus supplement, we are extending the period for exercising the rights until<B>&nbsp;5:00 p.m., Eastern Time, on April</B><B></B><B>&nbsp;9, 2024</B>.&nbsp;If you wish
to exercise your rights you must submit your subscription documents before the new expiration date of<B>&nbsp;5:00 p.m., Eastern Time, on April</B><B></B><B>&nbsp;9, 2024</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in the original prospectus supplement to the expiration date for exercise of rights are hereby amended as described
herein.&nbsp;All other descriptions, terms and conditions set forth in the original prospectus supplement remain unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rights which
are not exercised by the expiration date of the rights offering will expire and will have no value. You should carefully consider whether or not to exercise or sell your rights before the expiration date. <B>Once you have exercised your rights, your
exercise may not be revoked.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Exercising the rights and investing in our common stock involves significant risks. </B>We urge you
to read carefully the section entitled &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-23</FONT> of the original prospectus supplement and beginning on page 6 of the base prospectus, the section entitled &#147;Risk
Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, and all other information included or incorporated by reference in the prospectus and this prospectus supplement in
its entirety before you decide whether to exercise your rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the Company, our board of directors, any committee thereof, or
the Dealer Manager makes any recommendation to stockholders regarding whether they should exercise, sell or let lapse their rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
you have any questions or need further information about this rights offering, please contact Okapi Partners LLC, our information agent for this rights offering, at (855) <FONT STYLE="white-space:nowrap">208-8902</FONT> or via email at
<U>info@okapipartners.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this Amendment No.&nbsp;1 to prospectus supplement is March&nbsp;25, 2024. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
